Recent Quotes (30 days)

You have no recent quotes
chg | %

Quest PharmaTech Inc  

(Public, CVE:QPT)   Watch this stock  
Find more results for QPT
-0.005 (-4.55%)
Nov 23 - Close
CVE data delayed by 15 mins - Disclaimer
Currency in CAD
Range 0.10 - 0.10
52 week 0.09 - 0.19
Open 0.10
Vol / Avg. 14,000.00/43,406.00
Mkt cap 17.54M
P/E     -
Div/yield     -
EPS -0.04
Shares 167.09M
Beta 1.49
Inst. own     -

Key stats and ratios

Q3 (Jul '17) 2017
Net profit margin -16068.95% -153462.60%
Operating margin -11179.17% -167971.20%
EBITD margin - -167390.70%
Return on average assets -74.20% -35.47%
Return on average equity - -
CDP Score - -


8123 Roper Rd NW
+1-780-4481400 (Phone)
+1-780-4160324 (Fax)

Website links


Quest PharmaTech Inc. is a Canada-based pharmaceutical company. The Company, through its subsidiary, OncoQuest Inc., is developing immunotherapies for cancer treatment. It operates through two segments: biopharmaceutical/pharmaceutical products and consumer/cosmetic products. OncoQuest's technology platform includes a panel of tumor antigen specific monoclonal immunoglobulins, including CA125, MUC1, PSA, and Her2/neu, and the application of combinatorial immunotherapy. OncoQuest's lead product, oregovomab, is undergoing a Phase IIb clinical trial involving approximately 80 ovarian cancer patients in Italy and the United States. OncoQuest's pipeline of product candidates consists of four other monoclonal antibodies targeting certain tumor antigens that are presented in a range of cancers, including such cancers as breast, lung, pancreas, stomach and prostate. It also markets consumer health products around the world, including Bellus Skin serum, an anti-wrinkle skin care product.

Officers and directors

Lorne Meikle Independent Chairman of the Board
Ragupathy Madiyalakan Ph.D. Chief Executive Officer, Director
Hany Awadalla Chief Financial Officer, Senior Vice President
Thomas Woo Vice President - Product Development
Mark Lievonen Director
Shawn Shuguang Lu Director
Eric Shi MD, PhD Independent Director